Ascaltis Announces FDA IND Submission of ASC39, an Oral Selective Amylin Receptor Agonist for the Treatment of Obesity. Company announcement.
Ascaltis Announces FDA IND Submission of ASC39, an Oral Selective Amylin Receptor Agonist for the Treatment of Obesity. Company announcement.